Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff

Bristol-Myers Squibb is described as undervalued at 8.9x forward earnings, with patent cliff fears around Eliquis and Opdivo judged overblown. The Growth Portfolio now contributes 55% of revenue, grew 17% in FY2025, and is expected to keep growing at double-digit rates into 2026. Key upside catalysts are the August 2026 FDA decision on iberdomide and upcoming milvexian Phase 3 results, both cited as multi-billion-dollar opportunities.

Analysis

The market is still pricing BMY like a single-asset patent expiry story, but that framing misses the portfolio transition already underway. If the growth segment is now the majority of revenue and still compounding at a double-digit rate, the equity should migrate from a terminal-value multiple to a sum-of-parts re-rating as investors gain confidence that earnings power survives the cliff. That creates a classic second-order setup: even modest evidence of sustained growth can force quant models and value funds to de-risk the bear case simultaneously, supporting multiple expansion before any single new drug meaningfully contributes.

The key nuance is timing. The next 3-9 months are likely to be driven less by clinical readouts themselves than by how the Street updates peak-sales probabilities into FY26 estimates. A positive milvexian readout or credible FDA path for iberdomide would do more than add NPV; it would reduce the discount rate applied to the whole pipeline, because the market is currently assigning a steep execution haircut to BMY’s R&D engine. That makes upside asymmetric: the stock can rerate on confirmation, but the downside from a miss is partially cushioned by cash generation and the already-depressed multiple.

Competitive dynamics also matter. If BMY proves it can keep growth assets compounding, it pressures large-cap pharma peers with more visible cliff risk to defend their own pipelines more aggressively, which could spill into BD spend and M&A premiums across oncology/immunology. The contrarian view is that consensus is overestimating how quickly the patent-loss narrative converts into earnings collapse; the real risk is not a sudden profit air pocket but a slow, visible progression that the market can underwrite away. The main tail risk is a double miss on the upcoming catalysts, which would extend the skepticism another 6-12 months and keep the stock trapped despite cheapness.

Key Decisions for Investors

• Go long BMY over a 3-6 month horizon ahead of the iberdomide FDA date and milvexian data; attractive setup if the stock still trades near high-single-digit forward earnings with a 15-25% re-rating potential on even one credible pipeline de-risking event.
• Buy BMY Jan-2027 call spreads rather than outright calls to express upside from pipeline confirmation while limiting theta decay; this is best for investors who want exposure to a rerating without paying full premium for binary clinical risk.
• Pair trade: long BMY / short a more expensive large-cap pharma name with less visible near-term catalyst support and a similar patent-overhang profile; this isolates re-rating from absolute sector beta and benefits if the market rewards clearer post-cliff visibility.
• For event-driven accounts, reduce into the catalyst if the stock rallies sharply into the FDA decision and/or Phase 3 readout; implied upside is meaningful, but binary gap risk rises materially once the market starts pricing in success.
• If milvexian data disappoints, treat any 5-10% drawdown as a tactical add point only if the growth portfolio continues to print double-digit expansion; the thesis breaks on pipeline credibility loss, not on incremental noise.